Products Quality Lab Reports Knowledge Calculator FAQ 💬 Get in touch
Vesugen vial
Regeneration

Vesugen.

Available Variants
20 mg

Research area: Regeneration

🛡️
For research purposes only. Not intended for use in humans or animals.
Regeneration research

About Vesugen

Vesugen is studied in tissue regeneration and repair research, including cell and animal models. An epigenetic regulation of vascular endothelial cell proliferation is proposed; the cited paper described an effect on the proliferation marker protein Ki-67 in aged cell cultures.

Research Application

Researched as a vascular bioregulator in the context of vascular aging. The evidence base is limited to very few papers from the same institution and is preclinical.

Important to know

Claims circulating online are often not backed by valid clinical data. Treat all information as a starting point for your own scientific research, not as usage guidance.

20 mg
Lyophilized powder
Regeneration
see lab reports →
Tripeptide Lys-Glu-Asp (KED) per secondary sources; the peer-reviewed publication located does not state the sequence explicitly.
A vascular-targeted short peptide from Khavinson's group. Not an approved drug. One peer-reviewed publication (2014) discusses Vesugen in the context of vascular endothelial aging.

Sequence and regulatory status data are based on publicly available sources and refer to the compound in general, not to a specific product.

Research Overview

Studies on regenerative peptides are mostly derived from cell culture and animal models; comprehensive clinical data is typically still limited.

  • Khavinson VKh, Tarnovskaia SI, et al. Adv Gerontol. 2014;27(1):108–114. PMID 25051766

References without a PMID can be located via the respective publisher. This overview does not claim to be exhaustive.

Question about Vesugen?

We reply personally – via email or Telegram.

✉️ Email ✈️ Telegram
← Back to overview